** Shares of cell therapy company Talaris Therapeutics
up 8.2% at $3.1 premarket
** TALS on Tuesday after market close said its stockholders approved merger with biotech firm Tourmaline Bio; also announced a 1-for-10 reverse stock split of common stock
** TALS in June reported to merge with Tourmaline in an all-stock deal, creating a combined late-stage clinical biotech company listed on Nasdaq
** As per the terms, a wholly owned subsidiary of TALS will merge with Tourmaline
** The deal is expected to close on or around Oct. 19
** The combined co's common stock is expected to begin trading on Nasdaq on a split-adjusted basis on Friday, under the ticker symbol "TRML"
** As of last close, TALS stock up 176.5% so far this year
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.